Millennium Management
FBRX icon

Millennium Management’s Forte Biosciences FBRX Stock Holding History

Millennium Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-500
Closed -$37K – 6971
2021
Q3 		$37K Buy
+500
New +$277K ﹤0.01% 6617

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Millennium Management's FBRX Position: Q1 2026 in Review

Millennium Management increased its Forte Biosciences (FBRX) stake by 37% in Q1 2026, buying an estimated $2.63M and bringing the position to 337,983 shares worth $8.75M. The position accounts for ﹤0.01% of the portfolio, ranked #2299.

Millennium Management first reported a position in FBRX in Q1 2018 and has held it in 22 quarters since. 68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.

  • Millennium Management held 337,983 shares of Forte Biosciences worth $8.75M as of Q1 2026.
  • Millennium Management bought 91,298 Forte Biosciences shares in Q1 2026, an estimated $2.63M.
  • Forte Biosciences made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2299 holding.
  • Millennium Management first reported a position in Forte Biosciences in Q1 2018 and has held it in 22 quarters since.
  • 68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.